PRTC PureTech Health

PureTech Health to Present at Piper Jaffray 2017 Healthcare Conference

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced that Bharatt Chowrira, PhD, JD, President and Chief of Business and Strategy at PureTech Health, will present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017, at 9:10am EST at the Lotte New York Palace in New York, NY.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the “BIG” axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, the Company is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies that includes two pivotal stage programs, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programs. PureTech’s rich research and development pipeline has been advanced in collaboration with some of the world’s leading scientific experts, who along with PureTech's team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

EN
22/11/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PureTech Health

Puretech Health: 4 directors

Four Directors at Puretech Health bought 234,640 shares at between 123p and 125p. The significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc 08-Apr-2025 / 14:46 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(...

Liberum Research Team
  • Liberum Research Team

LIBERUM: Morning Comment

SAS Sentiment and Screens, Commodity snapSHOT, IAG, Endeavour Mining, Hargreaves Lansdown, Trainline, SIG, Cake Box, Aptamer, Market Highlights

Liberum Research Team
  • Liberum Research Team

LIBERUM: UK Small & Mid Cap Dispatches

SAS Sentiment and Screens, Commodity snapSHOT, Trainline, SIG, Cake Box, Aptamer, SMID Market Highlights

Liberum Research Team
  • Liberum Research Team

UK Small & Mid Cap Dispatches: Strategy - Equity market horse race, Al...

Strategy - Equity market horse race, Alts M&A up significantly in April, PureTech Health, Ferro-Alloy Resources, SMID Market Highlights

ResearchPool Subscriptions

Get the most out of your insights

Get in touch